Tevogen Inc. (NasdaqGM: TVGN)
Health Care · Biotechnology · US
$6.75
-1.75% today · -85.7% 1Y
Tevogen Inc. (NasdaqGM: TVGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.99M and employs 18 people.
Over the last twelve months the share price has lost 85.7%, trading between 3.64 and 49.50.
Tweenvest scores Tevogen Inc. across four factors: quality 1/100. Its strongest factor is quality.
TVGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.99M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -6.32
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- $49.50
- 52-week low
- $3.64
- Avg volume (3M)
- —
- Shares outstanding
- 4.22M
- Employees
- 18
- Next earnings
- —
About Tevogen Inc.
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
- Founded
- 2020
- Listed since
- Jan 5, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.